First patients receive experimental cancer drug in groundbreaking safety trial
NCT ID NCT07189403
Summary
This is the first human trial of an experimental drug called DS9051b for people with advanced adrenal gland cancer or metastatic prostate cancer that has stopped responding to standard hormone treatments. The main goal is to find a safe dose and understand the drug's side effects in about 40 participants. Researchers will also look for early signs that the drug might help control these difficult-to-treat cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brown University
RECRUITINGProvidence, Rhode Island, 02903, United States
Contact
-
Centre Oscar Lambret
NOT_YET_RECRUITINGVillejuif, 94800, France
Contact
-
Columbia University
NOT_YET_RECRUITINGNew York, New York, 10032, United States
Contact
-
Florida Cancer Specialists
RECRUITINGSarasota, Florida, 34232, United States
Contact
-
Oncopole Claudius Regaud
RECRUITINGToulouse, 31100, France
Contact
-
Royal Marsden
NOT_YET_RECRUITINGLondon, SW3 6JJ, United Kingdom
Contact
Conditions
Explore the condition pages connected to this study.